ArticleQuantitative imaging in medicine and surgery2026
Single-view echocardiography-based deep learning for pulmonary hypertension detection: a multi-level supervised and explainable approach.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early identification of pulmonary hypertension (PH), particularly mild disease, remains challenging. We aimed to develop and validate a deep learning (DL) model for noninvasive PH screening using single-view transthoracic echocardiography (TTE), without reliance on Doppler measurements. Methods: In this retrospective study, apical four-chamber (A4C) TTE cine loops were collected between January 2023 and June 2025. A total of 144 patients with PH confirmed by right heart catheterization (RHC), 17 RHC-confirmed non-PH patients, and 95 non-PH controls defined by TTE under strict inclusion criteria were included. An additional temporally independent validation cohort of 40 RHC-confirmed subjects was enrolled between December 2025 and May 2026. Multiple DL architectures were evaluated for detecting PH. Model performance was assessed at both sample and patient levels using the area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity. Results: A total of 256 patients with 318 TTE examinations were included for model development and independent validation, and an additional 40 RHC-confirmed subjects with 40 TTE examinations were included for temporal validation. The multi-level supervised model achieved the best performance among the evaluated architectures, with a patient-level AUROC of 1.000 [95% confidence interval (CI): 0.998-1.000], sensitivity of 0.954, and specificity of 1.000 in the independent validation cohort. In the temporal validation cohort, the model achieved an AUROC of 0.932 (95% CI: 0.843-0.992), with sensitivity of 0.875, specificity of 0.813, and accuracy of 0.850. In an analysis of 50 RHC-confirmed subjects, the DL model achieved an AUROC of 0.937 (95% CI: 0.865-0.987) for distinguishing mild PH from non-PH, with sensitivity of 0.857 and specificity of 0.864, compared with AUROCs of 0.607-0.825 for conventional echocardiographic parameters. Conclusions: We developed an interpretable DL framework based on single-view A4C echocardiography for noninvasive PH assessment. The model showed promising performance, including preserved sensitivity for mild PH. Further multicenter prospective validation is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.